Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan - JSON Representation

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "379738",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2025-07-01T16:36:53.204Z"
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 379738</b></p><a name=\"379738\"> </a><a name=\"hc379738\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-07-01 16:36:53+0000</p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Evidence/379738\">https://fevir.net/resources/Evidence/379738</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/379738</p><p><b>name</b>: Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan</p><p><b>title</b>: Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan</p><p><b>citeAs</b>: </p><div><p>Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 379738. Revised 2025-07-01. Available at: https://fevir.net/resources/Evidence/379738. Computable resource at: https://fevir.net/resources/Evidence/379738#json.</p>\n</div><p><b>status</b>: Active</p><p><b>author</b>: Joanne Dehnbostel: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Part Of</td><td><a href=\"Composition-375280.html\">Outcome Measure Report for QUARTET USA Trial</a></td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"EvidenceVariable-375183.html\">GroupAssignment: Quadpill vs. Candesartan</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-375202.html\">Hypertension Control at 12 weeks</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000182}\">odds ratio</span></p><p><b>quantity</b>: 2.85</p><p><b>numberAffected</b>: 32</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Extension</b></td><td><b>NumberOfParticipants</b></td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td/><td>62</td><td>53</td></tr></table><blockquote><p><b>attributeEstimate</b></p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000196}\">confidence interval</span></p><p><b>level</b>: 0.95</p><p><b>range</b>: 0.94-8.59</p></blockquote><blockquote><p><b>attributeEstimate</b></p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/sevco STATO:0000700}\">p-value</span></p><p><b>quantity</b>: 0.063</p></blockquote></blockquote></div>"
  },
  "url" : "https://fevir.net/resources/Evidence/379738",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/379738",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "name" : "Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan",
  "title" : "Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan",
  "citeAs" : "Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 379738. Revised 2025-07-01. Available at: https://fevir.net/resources/Evidence/379738. Computable resource at: https://fevir.net/resources/Evidence/379738#json.",
  "status" : "active",
  "author" : [
    {
      "name" : "Joanne Dehnbostel"
    }
  ],
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatesTo" : [
    {
      "type" : "part-of",
      "targetReference" : {
        🔗 "reference" : "Composition/375280",
        "type" : "Composition",
        "display" : "Outcome Measure Report for QUARTET USA Trial"
      }
    }
  ],
  "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "variableDefinition" : [
    {
      "variableRole" : "population",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/375183",
        "type" : "EvidenceVariable",
        "display" : "GroupAssignment: Quadpill vs. Candesartan"
      }
    },
    {
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/375202",
        "type" : "EvidenceVariable",
        "display" : "Hypertension Control at 12 weeks"
      }
    }
  ],
  "statistic" : [
    {
      "statisticType" : {
        "coding" : [
          {
            "system" : "https://fevir.net/sevco",
            "code" : "STATO:0000182",
            "display" : "odds ratio"
          }
        ]
      },
      "quantity" : {
        "value" : 2.85
      },
      "numberAffected" : 32,
      "sampleSize" : {
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/number-analyzed",
            "valueUnsignedInt" : 60
          }
        ],
        "numberOfParticipants" : 62,
        "knownDataCount" : 53
      },
      "attributeEstimate" : [
        {
          "type" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000196",
                "display" : "confidence interval"
              }
            ]
          },
          "level" : 0.95,
          "range" : {
            "low" : {
              "value" : 0.94
            },
            "high" : {
              "value" : 8.59
            }
          }
        },
        {
          "type" : {
            "coding" : [
              {
                "system" : "https://fevir.net/sevco",
                "code" : "STATO:0000700",
                "display" : "p-value"
              }
            ]
          },
          "quantity" : {
            "value" : 0.063
          }
        }
      ]
    }
  ]
}